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Abstract
Gene set methods aim to assess the overall evidence of association of a set of genes with a phenotype, such as disease or a
quantitative trait. Multiple approaches for gene set analysis of expression data have been proposed. They can be divided
into two types: competitive and self-contained. Benefits of self-contained methods include that they can be used for
genome-wide, candidate gene, or pathway studies, and have been reported to be more powerful than competitive
methods. We therefore investigated ten self-contained methods that can be used for continuous, discrete and time-to-
event phenotypes. To assess the power and type I error rate for the various previously proposed and novel approaches, an
extensive simulation study was completed in which the scenarios varied according to: number of genes in a gene set,
number of genes associated with the phenotype, effect sizes, correlation between expression of genes within a gene set,
and the sample size. In addition to the simulated data, the various methods were applied to a pharmacogenomic study of
the drug gemcitabine. Simulation results demonstrated that overall Fisher’s method and the global model with random
effects have the highest power for a wide range of scenarios, while the analysis based on the first principal component and
Kolmogorov-Smirnov test tended to have lowest power. The methods investigated here are likely to play an important role
in identifying pathways that contribute to complex traits.
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Introduction
With the advent of high-throughput technologies, such as
microarrays, complete genome-wide studies of genomic predictors
of diseases have become common. Many diseases or phenotypes
are expected to involve complex relationships of gene products
within the same molecular pathway or functional gene set.
Therefore, pathways or gene sets, as opposed to single genes,
may better reflect the true underlying biology and may be more
appropriate units for analysis. Pathway or gene set methods for
analysis of expression data incorporate prior biological knowledge
into the statistical analysis by evaluating the overall evidence of
association of a phenotype with expression of all genes in a given
pathway or gene set. Application of such methods may enable the
detection of more subtle effects of multiple genes in the same
pathway that may be missed by assessing each gene individually.
Moreover, the incorporation of biological knowledge in the
statistical analysis may aid researchers in the interpretation of
results.
Within the last few years, multiple approaches for gene set
analysis have been proposed for both expression and SNP data.
The various methods can be divided into two types: competitive
and self-contained [1]. Competitive methods compare the results
for genes within the gene set with results for genes outside the gene
set (complement) to determine whether genes in a particular gene
set are associated more with a phenotype as compared to genes
outside the gene set. Two widely used competitive gene set
methods for analysis of gene expression studies are gene set
enrichment analysis (GSEA) [2], which uses a Kolmogorov–
Smirnov test, and DAVID [3], which uses a Fisher’s exact test.
Self-contained methods, in contrast to competitive methods, only
consider results within a pathway or gene set of interest. Because
competitive methods require a comparison between results within
a gene set to those outside the gene set, these tests cannot be
applied in a study that only measured expression in a particular
candidate pathway or gene set. In contrast, self-contained methods
can be used for genome-wide studies as well as candidate gene or
pathway studies. For more discussion on existing methods for gene
set analysis, we refer the reader to Goeman and Buhlmann [1] and
Allison et al [4].
Let S represent a gene set of interest and S
C represent the
complement of S. The null hypothesis of self-contained gene set
methods is Ho
SC: Gene expression levels of all genes in S are NOT associated
with the phenotype, while the null hypothesis for competitive methods
is Ho
C: Genes in S are associated with the phenotype as much as genes in S
C.
The self-contained approaches are more powerful for testing the
H0
SC hypothesis and allow for subject-level sampling or permu-
tation methods for estimating the empirical null distribution of the
test statistic, while the competitive methods do not [1].
Liu et al [5] compared three self-contained methods for binary
phenotypes: the Global Test of Goeman et al. [6], that involves a
global model with random effects, the ANCOVA Global Test of
Mansmann and Meister (2005) [7] and SAM-GS (2007) [8], and
found that SAM-GS slightly out-performed the Global Test and
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contained gene set methods and the competitive GSEA method
[2] using three microarray studies and concluded that the self-
contained methods of SAM-GS, Global test and ANCOVA
Global outperformed GSEA. However, general conclusions
regarding the relative performance of the investigated methods
could not be made, as no simulation studies were completed.
Although SAM-GS is only applicable to data with binary
endpoints, an extension of SAM-GS recently introduced by
Adewale et al [10] is applicable to diverse phenotypes, including
binary, multiclass, continuous, and survival endpoints. Tsai and
Chen [11] proposed using a MANOVA test for gene-set analysis
and compared it to several methods including principal compo-
nent analysis, SAM-GS, GSEA, MaxMean, analysis of covariance,
and a global test. Based on simulation results and real data analysis
they found the MANOVA approach appeared to perform best,
but concluded that most methods, except GSEA and MaxMean
were generally comparable in terms of power. A limitation of the
MANOVA method of Tsai and Chen [11] (2009) is that it is only
applicable to categorical outcomes data.
In this paper, we present an extensive study of ten methods for
conducting a self-contained gene set analysis to test the hypothesis
H0
SC. Using the most extensive simulation study to date (over 2000
simulation scenarios and ten self-contained gene set analysis
approaches), we investigated previously proposed methods and a
newly proposed method, which combines the ideas of Fisher’s
Method [12] and Tail Strength [13]. We limited our study to self-
contained gene set methods that can be used for continuous,
binary or time to event endpoints/phenotypes, and allow for the
inclusion of covariate information. The following gene set methods
were assessed: Kolmogorov–Smirnov test (KS), Fisher’s method
(FM), Stouffer’s method (SM), tail strength (TS), a novel modified
tail strength statistic (MTS), global model with fixed effects
(GMFE), global model with random effects (GMRE), and
principal component analysis (PCA). These methods can be
divided into those based on summaries of results for individual
expression probes (e.g., p-values) (FM, SM, KS, TS, MTS) and
those based on joint modeling of all data for a given pathway
(PCA, GMRE, GMFE). The simulation scenarios varied accord-
ing to: number of genes in a gene set, number of genes associated
with the phenotype, effect sizes, correlation between expression of
genes within a gene set, and the sample size.
In the following sections we briefly describe the various self-
contained gene set methods for analysis of gene expression data
and provide details of the data simulation. We then present results
from the extensive simulation study that assessed the statistical
performance of the various gene set methods. For illustration of
the methods, we also present results from a pharmacogenomic
study of the drug gemcitabine.
Materials and Methods
Gene set analysis methods based on association p-values
In following sections we describe several gene set approaches for
testing the null hypothesis H0
SC (expression levels of all genes in a
gene set are not associated with the phenotype) that use p-values
from separate tests of association of the phenotype with the
expression of each gene in the gene set. All of these approaches
rely on first testing for association between the phenotype and the
expression measured by each of m probes individually. Let pi
represent the p-value from the test of the null hypothesis Hoi, i=1,
2, …, m (Hoi: expression measured by i
th probe is not associated
with the phenotype). The tests used to calculate pi’s will depend on
the type of phenotype. For example, for a continuous phenotype,
such as glucose level, the p-values for association with gene
expression could be based on a linear regression model. Any
appropriate parametric or non-parametric method can be used to
calculate the pi’s; however, power for the GSA will dependent on
the use of a powerful method for analysis of data for individual
expression probes. The p-values for these m tests are then used to
calculate a single test statistic and p-value for testing H0
SC.
Throughout this paper Y denotes a vector of size n61 that
contains continuous phenotypic values for the n subjects, and X
represents a matrix of size n6m that contains the gene expression
values for the m genes within the gene set S measured on the n
subjects.
Kolmogorov-Smirnov test. The Kolmogorov-Smirnov (KS)
test is a goodness of fit test that determines if a given empirical
distribution, F(x), differs significantly from a hypothesized
distribution, Fo(x). KS is one of the most useful and general
nonparametric methods for testing goodness of fit, as it is sensitive
to differences of the empirical cumulative distribution function
from the hypothesized function, in both location and shape. In the
context of testing H0
SC, the KS test for goodness of fit can be
applied to determine if the distribution of the observed p-values
differs from the distribution under the ‘‘null’’ hypothesis. In
particular for gene set analysis, we are interested in testing if the
observed p-values are smaller than expected under the null
distribution using the one-sided test statistic dz~max SN x ðÞ { ½
F0 x ðÞ   , with SN X ðÞ representing the cumulative step-function of a
sample. Significance for d+ can be assessed using the Kolmogorov
distribution or Monte Carlo methods. We applied the KS test
using a Uniform(0,1) reference (null) distribution; however, to
avoid reliance on the null U(0,1) distribution of probe-specific p-
values, we used Monte Carlo simulations to determine significance
level of the KS-test statistic d+.
Fisher’s method. Fisher’s method (FM) [12] and variations
of Fisher’s method [14,15,16,17] have been used extensively for
combining results from multiple statistical tests. See Zaykin et al
[16] for a brief review of modifications of Fisher’s method for
combining p-values. The original Fisher’s method for combining
independent p-values is based on the fact that since under the null
hypothesis pi,Uniform(0,1), 22log(pi) follows a Chi-squared
distribution with 2 degrees of freedom (x2
df~2). Therefore, the
test statistic F~{2
P m
i~1
log pi ðÞ ~{2log P
m
i~1
pi
  
follows a Chi-
squared distribution with degrees of freedom 2*m (x2
2m). It has been
shown that this method of combining p-values from independent
tests is asymptotically optimal (among essentially all methods) [18].
As opposed to relying on the asymptotic distributions that assume
independent p-values, we used a Monte Carlo approach to
determine the empirical p-values of the FM tests.
Stouffer’s method. Like Fisher’s method, Stouffer’s Method
(SM) [19] is also based on a sum of transformed p-values. However,
rather than using the log transformation of Fisher’s method, Stouffer
(1949) proposed using a normal transformation, and defined the test
statistic asZs~
P m
i~1
Zi=
ﬃﬃﬃﬃ
m
p
, with Zi~W{1 pi ðÞ ,w h e r eW{1 : ðÞis the
inversestandardnormalcumulativedistributionfunction[19].Inthe
setting in which the m tests are dependent (which will often be the
case in gene set analyses), permutation procedures can be utilized to
estimate the distribution of the test statistic. Again, to avoid reliance
on the asymptotic distribution of the gene-set association statistic,
which assumes independent probe-specific p-values, we used a
Monte Carlo approach to determine the empirical p-values of the
SM test.
Tail strength. The measure of tail strength (TS) proposed by
Taylor and Tibshirani [13] can also be used to perform self-
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ordered p-values (pi,) for the m expression probes in a gene
set. Next, define the tail strength as TS~ 1=m
   P m
j~1ð1{p j ðÞ
mz1=j
  
Þ. Under the null hypothesis, each pm,Uniform(0,1),
yielding Epj ðÞ
  
~j= mz1 ðÞ and therefore E(TS)=0. As discussed
by Taylor and Tibshirani (2006) [13], the tail strength measures
the deviation of the ordered p-values from the expectation under
the null hypothesis of no association. If overall the ordered p-
values are smaller than their expectation, TS .0 providing
evidence against the null hypothesis.
Since the statistic TS involves a summation, TS is approxi-
mately normal under the null hypothesis when m is large and the
p-values are independent. In practice, m may not be large (,20).
In addition, the assumption of independence between gene
expressions within a given pathway may not be valid. Thus, we
use permutations to determine the empirical distribution of TS
under the null hypothesis as a means for determining the p-value
for each pathway.
Modified tail strength. We propose a modification of the
tail strength method, by applying a log-transformation to p-values,
as is done in Fisher’s method. Let Xi=2log(p(i)), where p(i) are the
ordered p-values for the m expression probes, and define MTS~
1=m
P m
i~1
1{Xi 1=E(Xi)
     
. Under the null hypothesis of no
association, the random variable {log(pi) follows an expo-
nential distribution with rate parameter 1. Therefore, the
probability distribution of the order statistic Xi,i sXi*
Exp
P i
j~1
1=mzj{1
 !
, with expectation E(Xi)~
P i
j~1
1= m{jz1 ðÞ .
Under the null hypothesis, the expectation of the test statistic
MTS is 0, E(MTS)=0. In a similar fashion as tail strength [13],
the MTS measures the deviation of each ordered 2log(p-value)
from the expectation under the null hypothesis of no association.
However, by using the 2log(p-value), as opposed to the p-value
as done in the original Tail Strength method, we hope to gain
power for testing gene set effects. Since the assumption of
independence between genes within a given pathway may not be
valid, we again use permutations to determine the empirical p-
value of MTS for each pathway.
Gene set analysis method based on data modeling
Rather than relying on individual gene (probe set) p-values,
H0
SC can also be tested by jointly modeling the effects of
expression of genes within a pathway. The methods described in
following three sections.
Global model using fixed effects. Possibly one of the
simplest methods for completing a gene-set analysis is to fit a
regression model (linear, generalized linear, or Cox-proportional
hazards model) in which the expression levels of all m genes in the
gene set are included in the model as fixed effects (GMFE).
Assessment of association of the phenotype with the gene set is
then based on testing the null hypothesis H0 : b1~b2~:::~
bm~0 versus the alternative that at least one of the coefficients
differs from zero [20,21,22]. A limitation of this approach is that
the model is only estimable when m,n.
Global model using random effects. The global model
approach of Goeman et al [6] is based on a linear random effects
model in which the continuous phenotype is modeled as a function
of the expression values for the genes within the gene-set of interest
(GMRE). That is, Y is modeled as YDX*N(Xb,s2) with the gene
expression effects, b, having a common distribution with mean 0
and variance t2. Under the null hypothesis of no gene expression
effects on the phenotype, the variance of the expression effects is
zero (t2 =0), which can be tested with a score test [6]. This score
test is locally optimal for t2 =0 [23]. The method can be modified
to include covariates and/or other phenotypic types (e.g., binary,
survival, multi-class).
Principal components analysis. Principal Component
Analysis (PCA) is a broadly-applicable dimension-reduction
technique [24]. The basic goal of PCA is to reduce the
dimension of the data, which is accomplished by choosing p
components instead of the total set of m variables (gene expression),
where p%m. The components are linear combinations of the
original predictor variables. Gene set analysis using PCA was
completed in a manner similar to that described previously
[17,24,25]. In gene expression data analysis, the principal
components are created using linear combinations of gene
expression values. Previous applications of PCA to gene set
analysis used either only the first principal component [25,26] or
the top 3 to 5 principal components [17,27]. We used the top k
principal components needed to explain 80% (PCA80) of the
variation in the gene expression values within the gene set, along
with the methods based on the top one (PCA1) or top five
principal components (PCA1.5). The gene set association analysis
is then based on a likelihood ratio test for the effect of all the PCs
included in the model.
Permutation-based assessment of significance of gene
set association
Non-independence of gene-specific p-values due to correlation
of expression of genes in a gene set, and other factors such as small
sample size, can lead to departures of p-values from the expected
Uniform(0,1) distribution, even in the absence of expression-
phenotype association. Therefore, rather than relying on asymp-
totic distributions of the gene-set association statistics for the KS,
FM, SM, TS, MTS and GMRE methods, we use permutations to
obtain gene-set association p-values for these methods. First, the
phenotypic or response variable is randomly permuted keeping the
gene expression data fixed (and thus keeping the correlation
structure in the expression data). An association test for each gene
within the gene set is then computed based on the data set with the
permuted phenotype, and the gene set analysis statistic and
corresponding asymptotic p-value is calculated. This process is
repeated many times (e.g. 1,000 times), producing an empirical
distribution of the gene-set test statistic (and corresponding p-
values). The proportion of permutations in which the gene set
analysis p-value is smaller than the gene set p-value in the original
data provides the empirical estimate of the p-value for the gene set
test for association. Thus, although we use previously proposed
statistics, such as the F-statistics proposed by Fisher [12], as
summary statistics for a pathway, by using permutation to assess
significance of these statistics we remove the requirement for
specific null distributions (such as the assumption of the chi-square
distribution for the F-statistic). Therefore, none of the approaches
rely on the assumption that the probe-specific p-values, pi, are
uniformly distributed under the null hypothesis. Furthermore,
there is no assumption of independence of probe-specific p-values.
Data
Simulation Study. To assess the power and the type I error
rate for the various self-contained gene set approaches, an
extensive simulation study was completed. The simulated
scenarios varied according to: number of genes in a gene set,
number of associated genes, effect sizes for the associations,
correlation between expression of genes within a gene set, and the
Comparison of Gene Set Methods
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generated to estimate power or type I error rate.
Let n represent the number of subjects, and m represent the
number of genes (or expression probe sets) in a gene set. The
expression data for each subject was simulated from a multivariate
normal distribution, Xi 1|m ðÞ ,MVN 0,S ðÞ i=1,…,n. The covari-
ance matrix S was set to be either one in which there is no
correlation of expression values in a pathway so that S is diagonal,
or a structure in which all genes in the pathway are correlated the
same amount, i.e. exchangeable (with correlation r=0.1 or 0.3
and variance set to 1). Next, the quantitative phenotype (Yi) for
each subject was generated conditional on their gene expression
values, Yi,N m,s ðÞ with m~bXi. The specification of the effect
sizes b was varied according to the simulation scenario, with b=0,
1, 2, or 3 indicating: no, small, medium, and large effect size.
In total, 114 ‘‘null’’ scenarios, with no association of expression
at any gene in the pathway, were simulated to investigate type 1
error for a range of sample sizes (n=20, 100 or 500), gene set sizes
(m=10, 50, 100, or 500), error standard deviation (s=1 ,3 ,o r6 )
and levels of correlation between expression levels at different
genes (r=0, 0.1 or 0.3). For the null scenarios all bi =0. Details of
the simulation scenarios investigated are presented in Table S1.
In addition, 2268 scenarios were generated with gene expression
for at least one probe associated with the quantitative trait, to
investigate power of the gene set analysis methods. Simulation
settings for all ‘‘non-null’’ scenarios are presented in Table S2.A s
for the type 1 error simulations, sample size, gene set size, error
variance and correlation between expression at different probes
were varied for the power analyses. In addition, the number of
genes with expression associated with the quantitative trait, and
the effect sizes for these associations, were varied, by specifying a
non-zero vector of effect sizes, b.
In addition, we completed simulations with the simulated data
having similar correlation patterns to real data from a pharma-
cogenomic study of gemcitabine (described in subsequent section).
Gene expression data were simulated using the correlation
structure of the observed data, consisting of 31 probes within the
gemcitabine pathway. For these simulations, gene set size was
therefore fixed at 31. The phenotype was simulated under the
models outlined above, restricted to scenarios with the number of
effects being less than 31 probes. Sample sizes of 100 and 500 were
considered. Table S2 includes the 108 non-null simulation
scenarios based on the gemcitabine pathway correlation structure.
Similarly, Table S1 includes the 6 null simulation scenarios with
this correlation structure.
All simulated data sets were analyzed with the various self-
contained gene set methods. A test for the association of the
continuous phenotype with expression was calculated for each
probe using an F-statistic for the correlation between the gene
expression and phenotype, i.e. F~(n{2)½(r2=(1{r2) . P-values
were computed based on the F distribution with degrees of
freedom 1 (numerator) and n22 (denominator). Empirical p-
values for the KS, FM, SM, TS, MTS and GMRE methods were
all based on 1,000 permutations. Results for data generated under
the null hypothesis of no gene set association were used to assess
type 1 error rate, while results for data generated under the
alternative hypothesis were used to assess power. Power and type 1
error rates were estimated for all methods based on a 0.05
significance level. In addition to comparing mean power across
scenarios between methods, we investigated trends in power as a
function of characteristics of the simulation scenarios (e.g. sample
size, effect size). To summarize the extent of genetic contribution
of a gene set to the phenotype, we calculated R
2, the proportion of
variation in the quantitative phenotype due to gene expression
variation. R
2 was calculated as R2~b’Sb
 
b’Sbzs2   
. All
analyses were completed in R with code available from the
authors upon request.
Pharmacogenomic study of gemcitabine. Pancreatic
cancer is a rapidly fatal disease with a 5-year survival rate of less
than 5%. However, drug response to the standard chemotherapy
for pancreatic cancer, gemcitabine, varies widely among
individuals. Host variation in transport, metabolism and targets
for drugs used to treat pancreatic cancer may influence clinical
response to therapy. Variation in genes that play a role at each
step within the gemcitabine metabolic pathway could potentially
influence the quantity of drug transported into the cell, metabolic
inactivation of the drug, the rate of active drug formation and the
quantity of active drug reaching its target(s).
To develop hypotheses to be tested in translational studies
involving pancreatic cancer patients, cytotoxicity studies using a
cell-line model system were performed as previously described
[28]. Gemcitabine cytotoxicity data were collected at eight drug
dosages (e.g., 1000, 100, 10, 1, 0.1, 0.01, 0.001, and 0.0001 uM)
for 194 cell lines, and the phenotype IC50 (effective dose that kills
50% of the cells) was estimated using a four parameter logistic
model. In addition to IC50 phenotypic data, whole genome
expression data for these cell lines was obtained with the
Affymetrix U133 plus 2.0 expression array chip, which contains
over 54,000 probe sets designed based on build 34 of the Human
Genome Project. The mRNA expression array data were
normalized on the log2 scale using GCRMA methodologies
[29,30,31], and association of IC50 with expression of each probe
was investigated (see Li et al [28] for details of experimental
design, analyses and results).
In the previous analyses reported by Li et al [28], each
expression probe set was analyzed separately; however no gene set
analyses were performed. For illustration of the various self-
contained gene set methods, we applied the methods to investigate
the impact of gene expression in three gene sets on IC50. Based on
current knowledge of the function of genes in the gemcitabine
pathway, these genes are believed to play a role in response to the
drug gemcitabine (http://www.pharmgkb.org/do/serve? objId=
PA2036&objCls=Pathway). Thus, variation in expression of these
genes may impact the IC50 phenotype. We therefore chose this
pathway to illustrate the application of the methods, expecting that
we may obtain evidence of association of this candidate gene set
with the IC50 phenotype. The gemcitabine pathway contains 31
probe sets from the Affymetrix U133 plus 2.0 expression array. We
also applied the various GSA methods to a randomly selected set
of 20 genes (‘‘null’’ gene set) and another important drug
metabolizing pathway, the ‘‘glutathione’’ pathway, as this pathway
is the major metabolic pathway responsible for acetaminophen-
NAPQI detoxification [32,33] and response to platinum-contain-
ing drugs used in the treatment of ovarian and lung cancers [34].
The glutathione pathway contained 52 probe sets from the
Affymetrix U133 plus 2.0 expression array. Gene set analysis of
these two pharmacogenomic pathways and the null gene set was
performed as described for the simulated data. In performing GSA
for the gemcitabine cytotoxicity study, empirical p-values for the
KS, FM, SM, TS, MTS and GMRE methods were based on
10,000 permutations.
Results
Simulation study
Table 1 shows the mean type 1 error over all ‘‘null’’ scenarios
for all methods that were investigated. All methods had correct
type 1 error under all simulated scenarios (see Table S1 for
Comparison of Gene Set Methods
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the power of all methods for all ‘‘non-null’’ simulated scenarios.
The mean power across all scenarios is shown in the last column of
Table 1. Figure 1 displays pairwise comparisons of power, for all
methods, across all simulated scenarios. Looking at the rows of
scatterplots corresponding to FM and GMRE, the points fall on or
above the diagonal, indicating that these methods have higher
power than the other approaches over all scenarios investigated.
Consistent with this observation, these two methods had the
highest mean power across all scenarios. Although GMFE had
even higher mean power under situations when it could be
applied, this method was not applicable in most scenarios,
particularly those with small sample sizes. For the simulation
scenarios investigated here, KS and principal component analysis
with the top component (PCA1) had the lowest mean power. With
a small sample size of n=20 all of the principal component
methods had low power.
Overall, the novel MTS method led to improvements in power
over the existing TS method for large sample sizes (n=500), while
having lower mean power for small sample sizes (n=20). The
increase in power was more pronounced for large sample sizes and
models with fewer associated expression probes and low
correlation between expression probes. Among the PCA methods,
analysis based on principal components that explain 80% of the
variation (PCA80) had substantially higher power than analysis
based on either the top component (PCA1) or the top five
components (PCA1.5) for large sample sizes, except when there
was a high correlation between expression probes, in which case
all the PCA methods had similar performance. However, with the
small sample size (n=20) PCA80 had lowest power among the
investigated methods.
For all methods, power was generally higher at larger sample
size (Figure 2A), and when the correlation between expression
probes was higher (Figure 2B). For each simulation model, we
also calculated the proportion of probes associated with the
phenotype and R
2, the proportion of variation in the quantitative
phenotype explained by the gene expression values in the
pathway. As expected, power of all methods increased when more
expression probes were associated with the phenotype (Figure 2C)
and as R
2 increased (Figure 2D). Figures 2B–2D show the
relationship of power to the various model parameters (e.g.
number of associated probes, R
2) for sample size of n=100.
Similar plots for sample size of 20 and 500 are shown in Figure
S1. Figure 3 shows power of FM as a function of sample size,
correlation of expression values between probes, and R
2, again
demonstrating the increase in power with increasing sample size,
increasing correlation between probe-specific expression levels,
and increasing R
2. Similar patterns were observed for other
methods.
Gemcitabine pharmacogenomics
The gene set methods investigated by simulations were applied
to a pharmacogenomic study of the cancer drug gemcitabine, to
examine the impact of the gene set comprised of the gemcitabine
pathway, glutathione and null gene set on the drug-related
phenotype IC50 (effective dose that kills 50% of the cells).
Results of the GSA for the pharmacogenomics data with the
gemcitabine pathway, glutathione pathway and null gene set are
presented in Table 2. For the gemcitabine pathway, evidence of
gene-set association varies considerably between the methods, with
p-values for the pathway ranging from 0.002 for the PCA1.5
analysis to 0.341 for the PCA1 test. FM, GMRE, GMFE, PCA80
and PCA1.5 provided statistically significant evidence (p,0.05) for
association of expression of the gemcitabine pathway gene set with
the phenotype IC50. Overall, the patterns observed in the analysis
of the gemcitabine pathway mimic those patterns observed in the
simulation study for large sample sizes (n=100–500), with
PCA1.5, PCA80, FM, and GMRE resulting in the most significant
results while PCA1, KS and MTS resulted in the least significant
associations. In contrast, the results for the glutathione pathway
showed the GMFE approach produced the most significant results
(p=2.2761025), while the methods that produced the largest p-
Table 1. The mean type 1 error and power for all gene set methods averaged across all null (mean type 1 error) non-null (mean
power) simulation scenarios for sample sizes of 20, 100, and 500.
Mean Type 1 Error Mean Power
Type of Method Gene Set Method N=20 N=100 N=500 N=20 N=100 N=500
Based on combining
individual SNP p-values
Kolmogorov-Smirnov (KS) 0.047 0.048 0.053 0.533 0.751 0.831
Fisher’s Method (FM) 0.048 0.050 0.052 0.608 0.894 0.981
Stouffer’s Method (SM) 0.048 0.049 0.051 0.571 0.825 0.937
Tail Strength (TS) 0.048 0.049 0.052 0.573 0.807 0.876
Modified Tail Strength (MTS) 0.050 0.048 0.048 0.549 0.798 0.929
Based on modeling
the data
Global model using fixed effects
(GMFE)*
0.053 0.045 0.051 0.639 0.907 0.985
Global model using random
effects (GMRE)
0.048 0.050 0.053 0.604 0.900 0.984
PCA using 1st principal component
(PCA1)
0.050 0.050 0.049 0.537 0.717 0.821
PCA using1–5 principal components
(PCA1.5)
0.046 0.050 0.050 0.543 0.800 0.925
PCA using principal components
that explain 80% (PCA80)
0.049 0.047 0.052 0.489 0.861 0.975
*GMFE could not be applied in 27 out of 36, 18 out of 39, and 9 of the 39 simulation scenarios used to assess type 1 error at samples sizes of 20, 100, and 500,
respectively. GMFE could not be applied in 594 out of 720, 396 out of 774, and 198 of the 774 power scenarios with sample sizes of 20, 100, and 500, respectively.
doi:10.1371/journal.pone.0012693.t001
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specific p-value summaries (KM, FM, SM, MTS, TS) all produced
similar results (p-values between 0.01 and 0.03). Lastly, all
methods, except GMFE and PCA80, produced non-significant
results for the gene set containing a random selection of 20 genes.
Discussion
An extensive simulation study comparing a variety of self-
contained gene set methods for analysis of gene expression data
was carried out. Results demonstrated that among the methods
considered, Fisher’s method (FM) [12] and a global model with
random effects (GMRE) [6] have the highest power to detect gene
set effects. As compared to GMRE, the main advantage of FM is
that it can be applied when only summary statistics or p-values for
each gene expression probe are available. However, when original
expression data are not available, the permutation-based p-value
for the overall gene set effect cannot be obtained, and we must rely
on p-values based on asymptotic theory. This can lead to an
invalid test with inflated type 1 error when different expression
values within a gene set are correlated. The main advantage of
GMRE, on the other hand, is that it allows for estimation of effects
in the context of other effects within the pathway, and inclusion of
interaction effects. An investigation of the performance of various
gene set approaches in detecting pathway effects in the presence of
gene-expression interactions is warranted.
FM was more powerful than the other methods based on
combining probe-specific p-values that were considered. FM treats
p-values at the extreme of the distribution asymmetrically, being
more sensitive to small p-values than large p-values. This leads to
an advantage over methods such as Stouffer’s Method (SM) [19]
that avoids asymmetry by transforming p-values to normally
distributed variables and then using them in a one-sided test. SM is
therefore equally applicable to detecting deviations of p-values
from the null distribution due to an overrepresentation of p-values
close to 1, rather than p-values close to 0. However, as this is not
the goal of the overall test of association of a pathway with the
phenotype, this feature is not advantageous in this context. For
large sample sizes (n$100), the proposed MTS test statistic with
the use of a log transformation of the p-value resulted in higher
statistical power than the originally proposal TS measure.
However, the MTS test still falls short of both FM and GMRE
methods in terms of power.
Similar approaches can be considered in the context of analysis
of genotype data from single nucleotide polymorphisms (SNPs)
within genes that belong to a gene set. The key differences between
expression and genotype gene set data is that SNP-sets tend to be
much larger (more SNPs than expression probes map to a gene
set), and for SNPs there is a greater extent of correlation within a
gene set, resulting from linkage disequilibrium (LD) within genes.
Also, SNP data are ordinal (0, 1, or 2 minor alleles for each SNP)
and different ways of modeling such data can be considered (e.g.,
dominant, recessive genetic models).
In our simulation study we generated a continuous phenotype
that depended on a portion of expression values according to a
specific model. The methods investigated here, or simple
Figure 1. Pairwise scatterplot of power for the various methods for scenarios with standard deviation (s) of 6.0.
doi:10.1371/journal.pone.0012693.g001
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phenotypes, such as case-control status or time-to-event outcomes.
The p-value combination methods are particularly easily modified,
as the individual gene/probe set p-values can be based on any
appropriate method, such as logistic regression for a case-control
analysis.
The global model with fixed effects (GMFE) cannot be applied
to data with a large number of gene expression probes (number of
genes greater than number of subjects), due to the model being
non-estimable. Otherwise, all methods considered are relatively
easy to implement and computationally feasible. Although
calculating permutation p-values, as opposed to p-values based
on asymptotic distributions, is more time-consuming, we recom-
mend the use of permutations when the gene expression levels
within a gene set are correlated. Use of asymptotic distributions
assumes independence of gene expression levels and can lead to
highly inflated type 1 error rates when this is an invalid
assumption. For instance, with p-values based on the asymptotic
chi-squared distribution (detailed results not shown), the mean
type I error rates for FM across the null simulation scenarios
increased as the level of dependency between the genes increased,
with mean error rates of 0.051, 0.11, and 0.182 for correlation of
0.0, 0.1 and 0.3, respectively. It should also be noted that if an
appropriate testing method is not used to assess the association of
each gene within the gene set with the phenotype, the aggregation
of these results for determining the association of the gene set will
be invalid. Thus, when applying FM for gene set analysis, one
should choose an appropriate analysis method (and if possible, the
most powerful) for assessing the association of each gene with the
phenotype.
Application of the gene set methods to data from a
pharmacogenomics study provided evidence that the expression
of genes in the gemcitabine and glutathione pathways are
associated with the IC50 outcome following treatment of cell lines
with gemcitabine. The application of the various gene set methods
to the gemcitabine pharmacogenomic study demonstrates one of
the key advantages of self-contained methods: these methods can
be applied to a specific candidate pathway, without requiring
genome-wide data for other pathways. Analysis of specific
pathways of interest can be more powerful as it reduces the need
for correction for multiple testing.
The results obtained for the pharmacogenomics example are
consistent with the prior knowledge that the gemcitabine pathway
contains genes that play a role in individual response to the drug
gemcitabine. However, not all the gene set methods were able to
detect the association of the phenotype with this pathway. In
particular, the KS, SM, TS, MTS, and PCA method using only
the top component, did not detect a significant association at the
Figure 2. Plots of power for all methods. Power is plotted as a function of (A) sample size, (B) the correlation between expression values within
the gene set (r), (C) the proportion of probes associated with the phenotype, and (D) the calculated R
2, the proportion of variation in the quantitative
phenotype explained by the gene expression values in the pathway. The average power values are based on all simulated non-null scenarios. Plot (B)
excludes scenarios with between-probe correlation structure defined by the gemcitabine pathway, and only shows fixed-correlation scenarios (r=0,
0.1, 0.3). Plots (B), (C), and (D) are based on sample size of 100. Similar plots for sample sizes of 20 and 500 are shown in Figure S1. For plots (C) and (D)
a kernel smoother was used to fit a curve to the data. Scenarios with all expression probes being associated with the trait were excluded from plot
(C), as all the methods had very high power in this situation.
doi:10.1371/journal.pone.0012693.g002
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simulation study results, which demonstrated that these methods
tended to have lower power than the other gene set tests.
However, for the gemcitabine pathway, principal component
analysis with the top 5 PCs detected stronger evidence of gene-set
association than other approaches, even though in simulations this
was generally not the most powerful approach. This is not
surprising, as the actual power of each method for a given data set
depends on the underlying situation, such as the number of
expression probes truly associated with the outcome, the levels of
association, etc. Perhaps for the gemcitabine pathway, the top five
PCs were optimal for capturing the relevant variation in
expression as related to the IC50 outcome. This is also observed
in the analysis of the glutathione pathway, in which the GMFE
approach produced the most significant results. This also agrees
with the simulation study, in which, if possible to fit, the GMFE
Figure 3. Power of Fisher’s Method (FM) as a function of sample size, correlation of expression values between probes (r), and R
2
(proportion of variation in the quantitative phenotype explained by the gene expression values in the gene set).
doi:10.1371/journal.pone.0012693.g003
Table 2. Results from analysis of gemcitabine pathway, glutathione pathway and null gene set from the various gene set
methods.
Type of Method Gene Set Method
Glutathione Pathway
p-value
Gemcitabine pathway
p-value Null gene set
Based on combining
individuals SNP p-values
Kolmogorov-Smirnov (KS) 0.0178 0.250 0.447
Fisher’s Method (FM) 0.0121 0.016 0.126
Stouffer’s Method (SM) 0.0241 0.158 0.272
Tail Strength (TS) 0.0211 0.160 0.344
Modified Tail Strength (MTS) 0.0371 0.267 0.278
Based on modeling the data Global model using fixed effects (GMFE) 2.27610
25 0.032 0.004
Global model using random effects (GMRE) 0.0137 0.012 0.780
PCA using 1st principal component (PCA1) 0.3610 0.341 0.668
PCA using1–5 principal components
(PCA1.5)
0.2920 0.002 0.518
PCA using principal components that
explain 80% (PCA80)
0.00396 0.022 0.050
doi:10.1371/journal.pone.0012693.t002
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simulation results provide an overall power comparison across
methods for a wide range of situations.
In conclusion, over a variety of scenarios, the FM [12] with
empirical p-values or the GMRE [6] were the most powerful
analytical approaches for a self-contained gene set analysis.
Therefore, we recommend either the FM [12] with empirical p-
values or the GMRE [6] for the analysis of gene expression data
with self-contained gene set analysis.
Supporting Information
Table S1 Type I error rates for various simulations scenarios for
all gene set methods considered (excel file).
Found at: doi:10.1371/journal.pone.0012693.s001 (0.04 MB
XLS)
Table S2 Power for various simulations scenarios for all gene set
methods considered (excel file).
Found at: doi:10.1371/journal.pone.0012693.s002 (0.47 MB
XLS)
Figure S1 Plots of power for all methods as a function of the
correlation between expression values within the gene set (r), the
proportion of probes associated with the phenotype, and the
calculated R2 (the proportion of variation in the quantitative
phenotype explained by the gene expression values in the
pathway). The average power values are based on all simulated
non-null scenarios, with plots (A)–(C) being based on sample size of
20, and plots (D)–(F) being based on sample size of 500. The plots
of power as a function of correlation (A and D) exclude scenarios
with between-probe correlation structure defined by the gemcita-
bine pathway, and only shows fixed-correlation scenarios (r=0,
0.1, 0.3). For plots (B), (C), (E) and (F) a kernel smoother was used
to fit a curve to the data. Scenarios with all expression probes
being associated with the trait were excluded from plot (B) and (E),
as all the methods had very high power in this situation.
Found at: doi:10.1371/journal.pone.0012693.s003 (0.31 MB EPS)
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